Dr. Reddy’s Q4 Review – Strong U.S. Show; Margin Recovery Is Key: Prabhudas Lilladher
Bestinau got that-
Dr. Reddy’s Laboratories Ltd.’s Q4 FY22 U.S. and India revenues were healthy. We continue to expect steady earnings momentum and pick up in U.S. generic business along with cost optimisation.
Also, Dr. Reddy’s strong pipeline/new launches will drive steady growth in India and Rest of World markets.
We expect 13% earnings per share compound annual growth rate over FY22-24E (excluding of Revlimid).